Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1. These ...

Long-acting risperidone injection was released for marketing for the treatment of schizophrenia in the United States in October 2003. The drug was available in 45 countries as of December 2003.